Reuters -- The CEO of Regeneron Inc (REGN.O) said on Tuesday his company expects late-stage data by the first half of 2011 on its experimental drug for colorectal and lung cancer, and that it could show a safety advantage over Roche Holding AG’s (ROG.VX) blockbuster Avastin.
